The clinical features of gout have been well-recognised since ancient times. Knowledge of its underlying metabolic causes began towards the end of the eighteenth century with the discovery of uric acid in urinary calculi and gouty tophi, and during the nineteenth century Sir Alfred Garrod showed that the blood of gouty subjects contained an excess of uric acid which became deposited in crystalline form in the joints. The later work of Emil Fischer, establishing that uric acid was a purine compound and thus potentially related to the nucleic acid constituents adenine and guanine, and the improved methodology of uric acid determination by Folin and Dennis completed this part of the story.Other developments during the twentieth century have included, firstly, the realisation that hyperuricaemia and gout have many different causes; secondly, a swift advance, gained by biochemical, isotope, and cell-culture techniques, in our knowledge of purine metabolism, including the discovery by Seegmiller and his colleagues in 1967 of the first specific enzymatic defect (HGPRT deficiency) responsible for one special type of gout; and, thirdly, from the therapeutic aspect, a remarkable facility to control both the acute gouty attack and the level of uric acid in the blood.People who develop gout have usually lived for many years, unknown to themselves, with a raised